Life Insurance for Diabetics: What It Costs

Short answer: Yes, most people with diabetes can buy life insurance, because underwriting prices the pattern of blood sugar control and complications rather than the diagnosis name itself. A well managed case, with stable A1c, no major complications, and consistent care, commonly lands at standard rates or a modest rating through a table step or a flat extra. Type 1 diabetes, a recent diagnosis, poor control, and documented complications are what typically move the price higher, and simplified issue, guaranteed issue, and group coverage exist underneath fully underwritten policies for cases that need them.

A diabetes diagnosis on an application form tends to feel like a wall. Applicants read the health questions, assume the worst, and some avoid applying at all rather than find out what an insurer would actually say. That reaction is understandable, and it is usually wrong, because underwriting a chronic condition like diabetes is an exercise in pricing a pattern, not issuing a verdict on a diagnosis.

This breakdown walks through what a diabetes history actually changes in an application: how type 1 and type 2 are read differently, why A1c and complications carry more weight than the diagnosis label, what a managed case tends to cost against the advertised top rate, and what the routes underneath fully underwritten coverage, simplified issue, guaranteed issue, and group coverage, honestly cost. It sits beside our broader explainer on buying life insurance with a health condition, which covers the general mechanics of ratings and table steps, and our breakdown of underwriting classes, which explains the ladder itself. Nothing here diagnoses, manages, or gives medical guidance on diabetes. Every figure is constructed to show arithmetic, not to quote a market.

What the underwriter is actually asking about a diabetes history

An underwriter reading a diabetes disclosure is not weighing how serious the diagnosis sounds in the abstract. They are asking a narrower set of mechanical questions: when the diagnosis was made, which type, how it has been controlled over time, what the most recent A1c readings show, what medications are in use, and whether any complication has been documented. Those follow-on questions are where the price actually gets decided.

That framing explains why two applicants with the same diagnosis on paper can be priced very differently. Someone with eight years of stable A1c readings on one medication and no complications reads as a settled, well documented file. Someone diagnosed eighteen months ago, still adjusting medication, reads as an open question the underwriter has to price conservatively because the picture has not yet settled. The label on the chart is the same. The pattern behind it is not.

None of this is a comment on how anyone should manage their diabetes, which remains a matter between a person and their own physician or endocrinologist. The point here is narrowly administrative: an insurer can only read what the file shows, so a complete, current, and accurate record does more for an applicant than any explanation offered on the phone afterward.

The vocabulary of a rated diabetes file

The same handful of words apply here as to any rated condition, and knowing them in advance takes the sting out of an offer letter. A class is the tier a file was sorted into. A rating, expressed as table steps, is a substandard offer priced as a multiple of the standard rate. A flat extra is a fixed dollar charge per thousand dollars of coverage, added on top of the class premium. A postponement means the insurer will look again later and has said when. A decline means one company will not offer coverage today.

Only the last of those closes anything, and it closes it at a single company under a single manual. The other four describe an offer or a timing decision, which is why the first question worth asking after any letter is which of these five things actually happened, not whether the application was approved in some general sense.

Type 2 diabetes and what moves a file toward standard

Type 2 diabetes is the more common diagnosis underwriters see, and manuals are generally built with a fair amount of experience pricing it. The features that tend to move a file toward standard rates are a diagnosis that is not brand new, stable A1c readings in a commonly cited well-controlled range, consistent follow-up with a physician, a healthy weight trend, and the absence of any documented complication.

What tends to move a file the other way is the opposite pattern: a diagnosis within the last year or two, A1c readings that have climbed or swung widely, medication changes that suggest control is still being found, or an early complication noted in the chart. None of these close the file outright at every insurer, but they are the features a manual is built to price conservatively, because they describe a condition that has not yet settled into a predictable pattern.

Type 1 diabetes and why duration and complications matter

Type 1 diabetes tends to draw more underwriting attention than well-controlled type 2, mostly because it is almost always insulin-dependent, is commonly diagnosed earlier in life, and carries a different long-term risk profile in the manuals insurers use. That does not mean the condition is uninsurable. It means the file is more likely to need a full attending physician statement, more likely to be priced with a table rating rather than at standard, and more likely to benefit from being placed with an insurer whose manual is known to handle the diagnosis reasonably.

Duration and demonstrated stability carry real weight here. An applicant with many consecutive years of reasonably controlled type 1 diabetes, consistent endocrinology follow-up, and no complications is a meaningfully different file from someone a year or two removed from diagnosis, even when both disclose the same condition on the form. Working with a licensed independent agent who has placed type 1 files before tends to matter more here than almost anywhere else in this topic, because the spread between how different companies price the same history is unusually wide.

Age at diagnosis also shapes how a file reads, independent of current control. Someone diagnosed with type 1 diabetes as a young child and now decades into a well managed adulthood is often read more favorably than the raw years-since-diagnosis number alone would suggest, because the record shows a long, demonstrated track of stability rather than a condition still settling in. A newer diagnosis in adulthood, by contrast, has not yet had the chance to build that longer track record, which is part of why time since diagnosis is weighted the way it is later in this piece.

A1c, the number underwriters anchor to

A1c is a blood test that reflects average blood sugar over roughly the prior two to three months, and it is one of the clearest, most comparable data points an underwriter has for reading a diabetes file. A commonly cited target for good control is under 7 percent, though individual targets genuinely vary by clinician, by age, and by patient, so treat that figure as a commonly discussed reference point rather than a universal rule.

What matters more than any single reading is the trend. A series of A1c results that has sat in a stable, well controlled range for several years tells a very different story than one that has climbed, or one that bounces between well controlled and poorly controlled from visit to visit. Bringing recent lab results to the application, rather than a general description of how things are going, is one of the more effective things an applicant can do to help a file get read accurately the first time.

Complications: the feature that matters most

If one feature in a diabetes file moves the price more than any other, it is a documented complication. Kidney involvement, eye disease such as retinopathy, nerve damage, and cardiovascular disease are the ones that appear most often in underwriting questions, and each one describes damage that has already occurred rather than a risk that might occur later. That distinction matters because manuals generally price an existing complication more heavily than they price elevated risk alone.

A diagnosis with years of stable control and no complications noted anywhere in the record reads as a settled, low-attention file. The same diagnosis with an early complication, even a mild one, tends to draw a larger rating, a request for additional records from a specialist, or in some cases a referral to a different product entirely. This is also why a complete, current medical record is worth more here than almost anywhere else in this topic: an incomplete file gets priced conservatively because the underwriter cannot see what is actually there, and a missing specialist note can cost more in assumed risk than the note itself would have shown.

Insulin, oral medication, and what the regimen signals

The treatment regimen on a chart is read as part of the overall pattern rather than as a standalone verdict. Oral medication alone, for a case that is otherwise well controlled, is generally read as a lighter-weight signal than insulin dependence, partly because insulin use sometimes correlates with a more advanced or harder to manage case in the data underwriters train their manuals on.

That said, type 2 diabetes that has progressed to include insulin because oral medication alone was no longer enough is not automatically priced the same as type 1 diabetes. Duration, A1c trend, and the presence or absence of complications still carry most of the weight. Frequent changes in dosage or regimen, similar to frequent medication changes in any chronic condition, tend to read as a less settled picture, not because any one treatment is viewed negatively, but because the pattern of change itself is what is being priced.

What a diabetes file is read for

No insurer publishes how it weights a diabetes file, and any claim of exact weights would be an invention. What can honestly be shown is a sense of proportion, built for intuition rather than as a model of any real manual.

Read that split as an argument about documentation rather than about the diagnosis. The largest slices are all things a treating physician’s records can show directly, which is exactly why those records, not a verbal description, do most of the work in moving a file toward a better outcome.

Where a managed condition tends to land you

Abstract categories do not help anyone plan, so the chart below prices one hypothetical applicant across a realistic range of outcomes. Take a forty-five year old non-tobacco buyer applying for $500,000 of twenty year level term with a documented diabetes history in the file. Every figure is constructed to show relative distances, not to quote a market.

Two things fall out of that arithmetic. The distance from the advertised top class rate to standard, illustratively $35 to $55, is smaller than most applicants expect, and a stable, well documented history landing at standard is a good and common outcome even though the letter can read like a downgrade. The larger money sits in the rated range: four tables takes $55 a month to $110, which is $13,200 across a twenty year term, and that gap is what shopping the file, supplying complete records, and requesting reconsideration later are all competing for.

How a table rating is priced

A table rating is arithmetic layered on top of the standard rate. The insurer takes the standard premium for your age, coverage, and term, then adds a stated increment for each table step, and the sum is the premium. Steps are labelled with numbers at some companies and letters at others, and the systems generally map onto each other, though neither the labels nor the increments are standardized across the industry.

This article uses an illustrative increment of 25 percent of the standard rate per step because the arithmetic needs a number, and it says so every time. Your own offer states its own increment. What is genuinely useful about a rating, compared with a decline, is that it attaches to something nameable: the insurer decided a specific feature of the file, often the A1c trend or a complication, justified a specific number of steps, which means there is a question to ask and, later, an answer that can be revisited.

Flat extras and why they behave differently

A flat extra is not a multiplier on the class premium. It is a fixed dollar charge per $1,000 of coverage per year, added on top of whatever class the file earned, and it scales with the face amount you buy rather than with how the insurer graded you. On the illustration used throughout this piece, a flat extra of $2.50 per $1,000 a year on $500,000 of coverage adds roughly $104 a month on top of the base premium, which against an illustrative $55 standard rate more than triples the cost.

The feature worth checking is duration. Some flat extras run for a stated number of years, often tied to a specific recent event such as a new diagnosis or a recent complication, and drop off automatically once that period passes. A flat extra attached to a recent diagnosis and scheduled to end in three years is a very different commitment from one with no end date, so read your own offer letter for both the dollar amount and the term before deciding what it actually means for the policy.

What never to do about a diabetes diagnosis

A short list of moves turns a workable situation into an unnecessarily hard one, and they are worth stating directly. Do not omit or minimize a diagnosis, an A1c result, a medication, or a complication on the application. Life policies generally include a contestability period, commonly two years from issue, during which the insurer can investigate a claim, and the same records that would have been read at underwriting get read at a contested claim instead, where the consequence falls on your beneficiaries rather than on you.

Do not cancel an existing policy before a replacement is actually issued and in force; the gap between cancelling one and being approved for another is the most dangerous period in the entire process. Do not treat a single decline at one company as the market’s answer. And do not let anything about an insurance application influence how you manage your own diabetes, which remains a matter for you and your physician alone, separate from any administrative process described here.

Simplified issue and its narrower questions

Simplified issue policies skip the medical exam and replace it with a shorter set of health questions, often structured so that a yes answer to certain questions produces a decline rather than a priced rating. The trade is speed and reduced paperwork for a narrower band of acceptable answers and a higher cost per dollar of coverage than an equivalent fully underwritten policy.

For someone with well controlled diabetes, simplified issue is not automatically the better first stop. Its knock-out structure means a disclosed diagnosis can end the application outright at a company with no mechanism to price it, while a fully underwritten carrier reading the same file through a full manual might have offered standard rates or a modest rating. Our overview of no-medical-exam coverage compares these product types against each other in more detail.

Guaranteed issue and the graded death benefit

Guaranteed issue coverage asks no health questions at all, which makes it the product of last resort when fully underwritten and simplified issue options have both closed. Acceptance is generally limited only by age, face amounts are small, and the cost per dollar of coverage is the highest in the market. Almost all of these policies carry a graded death benefit, returning premiums paid plus a stated amount rather than the full face amount if death occurs within the first couple of years, after which the full benefit applies.

That structure is the arithmetic of pricing with no information at all, not a trap, but it defines what the product is realistically for. Guaranteed issue is aimed at final expenses, not at replacing income or clearing a mortgage. Our breakdown of final expense coverage covers that narrower use case and how to size it.

Group coverage through an employer as a floor

Basic group life offered through an employer is usually issued without individual underwriting, which makes it structurally valuable to anyone whose diabetes history has made the individual market slower or more expensive to navigate right now. There are no health questions and no rating, because the group as a whole is underwritten rather than each person inside it.

Supplemental amounts often behave differently, with a guaranteed issue limit available only at first eligibility or during a defined enrollment window, above which health questions apply. That timing detail is worth knowing before the window closes. Group coverage generally ends or becomes expensive when employment does, and the amounts are rarely sized to a mortgage and dependents, so it functions best as a floor to build on. Our explainer on group life insurance covers that side of the arrangement in more detail.

Why two insurers price the same file differently

Every insurer writes its own underwriting manual, encoding its own thresholds for A1c, its own follow-on questions for a given complication, and its own appetite for diabetes risk at a given age and face amount. None of these manuals are published, none are required to agree with each other, and they change over time as companies revise their underwriting philosophy and reinsurance arrangements.

The practical result is that the same file, with the same records and the same history, can produce different answers at different companies. That is not a loophole and not a sign that one company made a mistake. It is the direct consequence of an industry where classification is proprietary, and it is the strongest structural argument for treating a single company’s answer as one data point rather than as the market’s final word.

The attending physician statement and your treatment records

The single most influential document in a diabetes file is usually not produced by the applicant and not produced by the insurer. It is the attending physician statement, a set of records requested directly from the physician or endocrinologist who treats you, and it is what converts a described history into evidence of it.

Records carry weight because they are contemporaneous, created for a clinical purpose rather than an insurance one, and they show a sequence of visits, labs, and notes rather than a single snapshot. Requesting them is also the slowest step in most diabetes applications, for mundane reasons: the request has to reach the right practice, join a queue, and be compiled and released by someone who is not working to the insurer’s timeline. Knowing which practices hold your records and confirming correct contact details on the application are the two clerical steps that most reliably speed this part up.

What a decline actually means and the five moves after it

A decline is one company’s answer, under one manual, for one product, at one moment. It is not a statement about the whole market, and it is not permanent. It does carry a consequence worth knowing: applications ask whether you have previously been declined, postponed, or rated, and an industry information exchange holds coded details of prior applications, so a subsequent insurer usually knows. That is a reason to answer accurately, not a reason to stop applying.

There are five realistic routes after a decline. Ask the insurer what drove the decision, in writing, and find out whether it will say. Take the file to a licensed independent agent who can compare several carriers’ manuals before submitting anything formally. Consider a smaller face amount or a shorter term, since both change the risk being priced and some products decline at one amount while offering at another. Step down to simplified issue or, if necessary, guaranteed issue, accepting the trade-offs described above. And secure any group coverage available through work as the cheapest available floor while the rest is sorted out.

When control improves and the price can follow

A rating is not necessarily permanent. Most insurers have a process, usually called reconsideration or re-underwriting, for looking again at a rated policy once there is a documented period of further stability, and the outcome can be a reduced rating, a removed rating, or no change at all.

The mechanics matter more than the hope attached to them. It is a request, not an entitlement, and the insurer decides whether to reopen the file and what evidence it wants, generally records from a treating physician rather than a description from the applicant. Some carriers state a minimum waiting period before they will consider a request and some do not, so the only reliable answer is the one your own carrier gives when asked directly. On the illustration used throughout this piece, removing two table steps from a four table offer takes the premium from about $110 a month back to about $83, worth real money across the remaining years of a term.

Riders worth asking about

A few contract features are worth raising specifically when a diabetes history is part of the file, because they are easier to secure at issue than to add later. A conversion privilege on a term policy allows it to be exchanged for permanent coverage within a stated window without new evidence of insurability, which matters precisely because future health, including how a diabetes diagnosis progresses, is unknown. Our breakdown of policy riders covers what each feature is built to do in more detail.

Waiver of premium provisions, where available, keep a policy in force under defined circumstances the contract specifies, and accelerated death benefit provisions allow part of the death benefit to be paid during life under stated conditions, which can matter if a diabetes-related complication later becomes serious. All of these vary substantially by insurer and product, and none should be assumed from a summary sheet rather than the actual contract wording.

A worked illustrative example

Take the applicant used throughout: forty-five years old, non-tobacco, applying for $500,000 of twenty year level term, with type 2 diabetes diagnosed about four years ago, A1c stable in a commonly cited well-controlled range on oral medication, and no documented complications. The quoting engine shown at first contact displayed roughly $35 a month, the top class rate, which was never actually about this applicant.

The offer comes back standard, no rating, at an illustrative $55 a month. Against the $35 quote it looks like a jump; against the full range of outcomes for a disclosed diabetes history, it is one of the better realistic results and a common one for a stable, well documented file. A second applicant with the same diagnosis but an A1c trending upward over the past year and an early sign of kidney involvement noted at a recent visit comes back at four tables, an illustrative $110 a month, a gap of $660 a year against the first applicant’s offer.

Three years later, with improved A1c control and no progression of the kidney finding, that second applicant’s agent requests reconsideration. Two table steps come off, taking the premium from $110 to about $83 a month, a saving of roughly $4,590 across the remaining seventeen years of the term. None of these steps was guaranteed, and the request was worth making regardless.

Put your own numbers in

The companion beside this breakdown rebuilds the same illustration with your own figures. Set an age, the coverage you are applying for, the outcome printed on an offer, any flat extra attached to it, and the number of table steps you want to price a what-if reconsideration against, and every section carries your own version of the arithmetic.

Treat every output as a constructed illustration rather than a quote. It uses one simplified rate structure standing in for the many rate tables real insurers maintain, and applies a fixed 25 percent per table step because arithmetic needs a number. No output here predicts whether any diabetes history would be approved, rated, or declined. Settle the coverage amount first with the coverage calculator, then compare real offers from several insurers against each other rather than against anything printed here.

The bottom line

A diabetes diagnosis changes the price of life insurance far more often than it changes whether coverage can be bought at all. The ordinary path is an offer at standard or at a modest rating, the ordinary mistake is reading that offer against an advertised top class quote and concluding the market is closed, and the ordinary cost of that mistake is a household left uninsured while someone decides whether to apply.

Three things carry most of the practical weight. A1c trend, time since diagnosis, and the presence or absence of complications matter more than whether the chart says type 1 or type 2, so the records a treating physician holds are the most influential document in the file. Insurers genuinely disagree with each other on identical evidence, which makes a licensed independent agent worth more here than almost anywhere else in the buying process. And a rating is a priced decision rather than a verdict, so reconsideration later is a real route once control is stable and well documented. Size the amount with the coverage calculator, compare real offers using our quote comparison method, and keep every medical question with your own physician, where it belongs.

CoverKin is not an insurer, an agency, or a medical provider, and this breakdown is general educational material about how insurance underwriting handles a disclosed diabetes history, not medical, insurance, tax, or legal advice. Nothing above diagnoses, treats, or offers guidance on diabetes management, and every question about diagnosis, treatment, or complications belongs with a qualified physician, not with an insurance article. No insurer is named and no company’s underwriting manual is reproduced, because those manuals are proprietary and unpublished; thresholds, table increments, flat extra rates, graded benefit terms, and reconsideration rules are written individually by each company and vary by product, by state, and over time. Every premium, multiplier, share, and worked figure above, including the illustrative $35, $55, $83, $110, and $165 monthly premiums and the 25 percent per table step, was constructed to demonstrate arithmetic and is not a quote, an average, or a market rate. Before applying, accepting, replacing, or cancelling any coverage, put a licensed independent insurance professional between you and the paperwork, and read the actual contract rather than any summary of it.

Edited by Hamza Hai, MBA · Editor

Hamza Hai is the editor of CoverKin. She holds an MBA and reviews the site's articles against our editorial standards, checking that every figure is labelled for what it is, that nothing is presented as verified fact without a source the reader can check, and that the writing stays useful to a non-specialist.

How we research, write and review · LinkedIn